{"disease":{"id":"kidney-sparing","name":"kidney sparing"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06204406","title":"Prognosis of Patients With Upper Tract Urothelial Carcinoma Receiving Kidney-sparing Therapy","phase":"","overall_status":"RECRUITING","enrollment_count":106,"lead_sponsor_name":"RenJi Hospital","has_results":false},{"nct_id":"NCT07504939","title":"Multimodal Kidney-Sparing Strategy for High-Risk Upper Tract Urothelial Carcinoma","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":36,"lead_sponsor_name":"Peking University First Hospital","has_results":false},{"nct_id":"NCT07233252","title":"Nephron-sparing Treatment of Tislelizumab + Nab-Paclitaxel for Renal Pelvic Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":35,"lead_sponsor_name":"Tianjin Medical University Second Hospital","has_results":false},{"nct_id":"NCT07125547","title":"Neoadjuvant Tislelizumab + Nab-Paclitaxel Followed by Distal Ureterectomy for Ureteral Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":35,"lead_sponsor_name":"Tianjin Medical University Second Hospital","has_results":false}],"total":4},"guidelines":[],"source":"Drug Landscape verified database"}